Yüksek dereceli non-hodgkin lenfoma olgularında 77-04 protokolü tedavi sonuçlarımız: Tek merkez deneyim
Küçük Resim Yok
Tarih
2003
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Çocukluk çağı Burkitt ve lenfoblastik lenfomada yüksek doz kemoterapi protokollerinin etkin olduğunun gösterilmesinden sonra erişkinlerde de benzer tedavi yaklaşımları uygulanmaya başlamıştır. Bunlar arasında Magrath ve ark tarafından 1984 yılında yayınlanan 77-04 protokolü kliniğimizde Kasım 1993 ile Aralık 2001 tarihleri arasında toplam 17 hastaya uygulanmıştır. Hastalar tedaviyi iyi tolere etmiştir. En sık izlenen yan etkiler myelosupresyon ve mukozit olup tedaviye bağlı mortalite gözlenmemiştir. Tedavi sonunda 13 olguda tam remisyon (% 76,4) sağlanırken 1 olgu kısmi yanıt vermiş, 3 olgu ise tedaviye dirençli olarak kabul edilmiştir. Tüm olgularda medyan izlem süresi 107,5 aydır. Tam remisyon sağlanan 13 hastada 112 ayda hastalıksız sağkalım olasılığı % 48.6 olarak bulunmuştur. Dört evre IV lenfoblastik lenfoma olmak üzere nükseden 6 olgu kaybedilmiştir. Sonuçlar bu protokolün erişkin yüksek dereceli lenfomalarda oldukça etkin olduğunu, ancak evre IV lenfoblastik lenfomalı olgularda uzun süreli hastalıksız sağkalım açısından daha agressif tedavi yaklaşımlarının gerekli olduğunu göstermektedir.
After the demonstration of efficiency of high dose chemotherapy regimens in pediatric Burkitt and lymphoblastic lymphomas, adult patients were also begun to be treated with similar approaches. the 77-04 protocol reported in 1984 by Magrath et al has been administered to 17 adult patients between November 1993 - December 2001 in our hematology department. the patients tolerated the treatment considerably well. the most frequent side effects were myelosupression and mucositis. No mortality related to chemotherapy was observed. Complete remission was achieved in 13 patients (76.4 %) and partial remission in one patient. 3 patients were considered as refractory to the treatment. Median follow-up is 107.5 months in all patients. Disease free survival at 112 months was found to be 48.6 %. Six patients including four stage IV lymphoblastic lymphomas died with progressive disease. These results suggest that 77-04 chemotherapy regimen is highly efficient in high grade lymphomas; however for achieving long disease free survival in stage IV lymphoblastic lymphomas more aggressive treatment modalities are necessary.
After the demonstration of efficiency of high dose chemotherapy regimens in pediatric Burkitt and lymphoblastic lymphomas, adult patients were also begun to be treated with similar approaches. the 77-04 protocol reported in 1984 by Magrath et al has been administered to 17 adult patients between November 1993 - December 2001 in our hematology department. the patients tolerated the treatment considerably well. the most frequent side effects were myelosupression and mucositis. No mortality related to chemotherapy was observed. Complete remission was achieved in 13 patients (76.4 %) and partial remission in one patient. 3 patients were considered as refractory to the treatment. Median follow-up is 107.5 months in all patients. Disease free survival at 112 months was found to be 48.6 %. Six patients including four stage IV lymphoblastic lymphomas died with progressive disease. These results suggest that 77-04 chemotherapy regimen is highly efficient in high grade lymphomas; however for achieving long disease free survival in stage IV lymphoblastic lymphomas more aggressive treatment modalities are necessary.
Açıklama
Anahtar Kelimeler
Onkoloji
Kaynak
Türk Hematoloji Onkoloji Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
13
Sayı
3
